Drug Trial Radar · NCT03305016
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Nov 13, 2017
Primary completion
Mar 19, 2019
Study completion Mar 19, 2019
Sponsor
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/SIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Australia, and New Zealand.
Conditions
- Growth Hormone Deficiency, Pediatric
- Endocrine System Diseases
- Hormone Deficiency
- Pituitary Diseases
Interventions
TransCon hGHDrug
Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: 26 weeks
Locations
24 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
Neufeld Medical Group Inc.
Los Angeles, California
Center of Excellence in Diabetes and Endocrinology
Sacramento, California
Rocky Mountain Pediatric Endocrinology
Centennial, Colorado
Nemours Children's Health System
Jacksonville, Florida
Orlando Health Inc.
Orlando, Florida
Tallahassee Memorial Hospital
Tallahassee, Florida
University of Iowa
Iowa City, Iowa
Children's Minnesota
Saint Paul, Minnesota
University of Mississippi Medical Center
Jackson, Mississippi
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
NYU Winthrop Hospital
Mineola, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Cleveland Clinic Foundation
Cleveland, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Children's Diabetes and Endocrine Center
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Children's Medical Center
Dallas, Texas
Cook Children's Medical Center
Fort Worth, Texas
University of Virginia Children's Hospital
Charlottesville, Virginia
Children's Hospital of The King's Daughters
Norfolk, Virginia
Monash Children's Hospital
Clayton, Victoria, Australia
Stollery Children's Hospital
Edmonton, Alberta, Canada
The Liggins Institute, The University of Auckland
Grafton, Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.